Oxford Vaccine Less Effective Against South African Variant, Study Finds

A general view of AstraZeneca offices and the corporate logo in Cambridge, England, on July 18, 2020. Alastair Grant/AP Photo

The Oxford/AstraZeneca vaccine does not appear to offer protection against mild and moderate cases of the South African variant of the CCP virus, a new study has found.

In both the human trials and tests on the blood of those vaccinated, the vaccine “did not show protection against mild-moderate COVID-19” caused by the 501Y.V2 variant, the dominant CCP (Chinese Communist Party) virus strain in South Africa, said the study, which was first reported by the Financial Times.